<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dark grey bars) mice were treated with DT on 3 consecutive days starting one day before <i>S. ratti</i> infection. <b>A:</b> Percentage of Gr1<sup>+</sup>CD11b<sup>+</sup> cells in PBL was analyzed at the indicated time points. <b>BC:</b> BALB/c (white bars), BALB/c DEREG (black bars) were treated with DT and received an additional injection of anti-Gr1 mAb or isotype control one day before <i>S. ratti</i> infection. Percentage of Gr1<sup>+</sup>CD11b<sup>+</sup> cells in PBL of infected non-depleted mice was measured on day 1 p.i. (<b>B</b>) and number of adult parasitic females in the small intestine was counted on day 6 p.i. (<b>C</b>). Shown...
<p>(a), CD4<sup>+</sup>CD25<sup>−</sup> T cells from C57BL/6 mice were cultured with or without Gr-1...
<p>Infected p110δ<sup>D910A</sup> and WT mice were sacrificed at the indicated times and their liver...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
BALB/c Mcpt8-WT (open circles), BALB/c DEREG (closed circles), BALB/c Mcpt8-Cre (open squares) and B...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
<p>(A) Schematic overview of the experimental setup. Starting with streptomycin-pretreatment one day...
<p><b>A:</b> Experimental setup for α-IL-9 treatment either early (blue arrows) or late (grey arrows...
<p>C57Bl/6 mice (20 per group) were infected with 10<sup>6</sup> cfu/mouse of TIGR4 (A-D) or SRL1 (E...
<p><b>A:</b> Experimental setup is shown. <b>B:</b> Number of parasitic adults in the small intestin...
<p>C57BL/6 mice were left either untreated or infected with 5*10<sup>4</sup> PbTg iRBC (A). In addit...
<p>Representative flow cytometric dot plots of NK cells (<b>a</b>) and the percentage of NK cells (<...
<p><b>AB:</b> BALB/c Cpa3<sup>WT</sup> (white bars), BALB/c DEREG Cpa3<sup>WT</sup> (black bars), BA...
<p>Infected p110δ<sup>D910A</sup> and WT mice were sacrificed at the indicated times and their liver...
<p>Infected (CD11c-<i>cre</i>×Rosa26iDTR)<sub>F1</sub> mice were treated as shown in <a href="http:/...
<p>(a), CD4<sup>+</sup>CD25<sup>−</sup> T cells from C57BL/6 mice were cultured with or without Gr-1...
<p>Infected p110δ<sup>D910A</sup> and WT mice were sacrificed at the indicated times and their liver...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
BALB/c Mcpt8-WT (open circles), BALB/c DEREG (closed circles), BALB/c Mcpt8-Cre (open squares) and B...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
<p>(A) Schematic overview of the experimental setup. Starting with streptomycin-pretreatment one day...
<p><b>A:</b> Experimental setup for α-IL-9 treatment either early (blue arrows) or late (grey arrows...
<p>C57Bl/6 mice (20 per group) were infected with 10<sup>6</sup> cfu/mouse of TIGR4 (A-D) or SRL1 (E...
<p><b>A:</b> Experimental setup is shown. <b>B:</b> Number of parasitic adults in the small intestin...
<p>C57BL/6 mice were left either untreated or infected with 5*10<sup>4</sup> PbTg iRBC (A). In addit...
<p>Representative flow cytometric dot plots of NK cells (<b>a</b>) and the percentage of NK cells (<...
<p><b>AB:</b> BALB/c Cpa3<sup>WT</sup> (white bars), BALB/c DEREG Cpa3<sup>WT</sup> (black bars), BA...
<p>Infected p110δ<sup>D910A</sup> and WT mice were sacrificed at the indicated times and their liver...
<p>Infected (CD11c-<i>cre</i>×Rosa26iDTR)<sub>F1</sub> mice were treated as shown in <a href="http:/...
<p>(a), CD4<sup>+</sup>CD25<sup>−</sup> T cells from C57BL/6 mice were cultured with or without Gr-1...
<p>Infected p110δ<sup>D910A</sup> and WT mice were sacrificed at the indicated times and their liver...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...